IL312106A - Combination therapy of radionuclide complex - Google Patents

Combination therapy of radionuclide complex

Info

Publication number
IL312106A
IL312106A IL312106A IL31210624A IL312106A IL 312106 A IL312106 A IL 312106A IL 312106 A IL312106 A IL 312106A IL 31210624 A IL31210624 A IL 31210624A IL 312106 A IL312106 A IL 312106A
Authority
IL
Israel
Prior art keywords
compound
group
leu
cys
residue
Prior art date
Application number
IL312106A
Other languages
English (en)
Hebrew (he)
Inventor
Paola Daniela Aimone
Daniela Chicco
Maurizio F Mariani
Evren Zor
Original Assignee
Advanced Accelerator Applications
Novartis Ag
Paola Daniela Aimone
Daniela Chicco
Maurizio F Mariani
Evren Zor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications, Novartis Ag, Paola Daniela Aimone, Daniela Chicco, Maurizio F Mariani, Evren Zor filed Critical Advanced Accelerator Applications
Publication of IL312106A publication Critical patent/IL312106A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL312106A 2021-10-27 2022-10-27 Combination therapy of radionuclide complex IL312106A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163272447P 2021-10-27 2021-10-27
PCT/IB2022/060331 WO2023073603A1 (en) 2021-10-27 2022-10-27 Combination therapy of radionuclide complex

Publications (1)

Publication Number Publication Date
IL312106A true IL312106A (en) 2024-06-01

Family

ID=84365353

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312106A IL312106A (en) 2021-10-27 2022-10-27 Combination therapy of radionuclide complex

Country Status (11)

Country Link
US (1) US20250387523A1 (enExample)
EP (1) EP4422701A1 (enExample)
JP (1) JP2024539952A (enExample)
KR (1) KR20240093832A (enExample)
CN (1) CN118159304A (enExample)
AU (1) AU2022374887A1 (enExample)
CA (1) CA3234495A1 (enExample)
IL (1) IL312106A (enExample)
MX (1) MX2024004961A (enExample)
TW (1) TW202332473A (enExample)
WO (1) WO2023073603A1 (enExample)

Also Published As

Publication number Publication date
US20250387523A1 (en) 2025-12-25
CA3234495A1 (en) 2023-05-04
CN118159304A (zh) 2024-06-07
WO2023073603A1 (en) 2023-05-04
AU2022374887A1 (en) 2024-04-11
TW202332473A (zh) 2023-08-16
MX2024004961A (es) 2024-05-08
JP2024539952A (ja) 2024-10-31
EP4422701A1 (en) 2024-09-04
KR20240093832A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
AU2019407851B2 (en) Dual mode 18f-labelled theranostic compounds and uses thereof
US20230212549A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
US20240115745A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
US20220315554A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
US20250296971A1 (en) Gastric inhibitory peptide receptor ligands
US10919938B2 (en) Modified cyclopentapeptides and uses thereof
IL312107A (en) Cd73 compounds
AU2019469641B2 (en) Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders
Maschauer et al. Radiopharmaceuticals for imaging and endoradiotherapy of neurotensin receptor‐positive tumors
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
BR112015006453B1 (pt) Antagonista de grpr radiomarcado e composição terapêutica que o compreende
EP3763726A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
CN102711838B (zh) 胰岛成像用分子探针及其使用
DK2795317T3 (en) Composition for use in a cancer selection method
US12246076B2 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders
EP4455159A1 (en) Gastric inhibitory peptide receptor ligands with bio-distribution modifier
CN114845742B (zh) 用于癌症成像和治疗的经改性的grpr拮抗剂肽
EP4610269A1 (en) Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use
AU2026202638A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
JP2005068046A (ja) ソマトスタチンアナログ誘導体およびその利用
US20260077073A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof